Given studies showing the tumor-suppressive activity by inhibition of NF-κB4,5, this nuclear transcription factor became an attractive therapeutic strategy for novel antineoplastic compounds as several studies have revealed an important contribution of NF-κB to cancer progression and survival6. This evidence concerns the gene NFKB1 and cancer.